

November 27, 2013

## STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (ZZ-165) PEMBROLIZUMAB

PRONUNCIATION pem" broe liz' ue mab

THERAPEUTIC CLAIM Antineoplastic, immunomodulatory,  
immunotherapy

CHEMICAL NAMES

1. Immunoglobulin G4, anti-(human protein PDCD1 (programmed cell death 1)) (human-*Mus musculus* monoclonal heavy chain), disulfide with human-*Mus musculus* monoclonal light chain, dimer
2. Immunoglobulin G4, anti-(human programmed cell death 1); humanized mouse monoclonal [228-L-proline(H<sup>10</sup>-S>P)]<sub>4</sub> heavy chain (134-218')-disulfide with humanized mouse monoclonal κ light chain dimer (226-226':229-229')-bisdisulfide

## STRUCTURAL FORMULA

## Heavy chain

QQLVQSGVE	VKKPGASVKV	SCKASGYTFT	NYMYWVRQA	PGQGLEWMGG	50
INPSNGGTFN	NEKFKNRVTL	TTDSSTTTAY	MELKSLQFDD	TAVYYCARRD	100
YRFDMGFDYW	GQGTTTVIVSS	ASTKGPSVFP	LAPCSRSTSE	STAALGCLVK	150
DYFPEPVTVS	WNSGALTSGV	HTFPAVLQSS	GLYSLSSVVT	VPSSSLGTKT	200
YTCNVDPKPS	NTKVDKRVES	KYGPPCPPCP	APEFLGGPSV	FLFPPKPKDT	250
LMISRTPEVT	CVVVDVSDQED	PEVQFNWYVD	GVEVHNAKTK	PREEQFNSTY	300
RVVSVLTVLH	QDWLNGKEYK	CKVSNKGLPS	SIEKTISKAK	GQPREPQVYT	350
LPPSQEEMTK	NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN	YKTTTPVLDL	400
DGSFFLYSRL	TVDKSRWQEG	NVDFSCVMHE	ALHNHYTQKS	LSLSLGK	447

## Light chain

EIVLTQSPAT	LSLSPGERAT	LSCRASKGVS	TSGYSYLHWY	QQKPGQAPRL	50'
LIYLYSYLE	GVPARFSGSG	SGTDFTLTIS	SLEPEDFAVY	YQCQHSRDLPL	100'
TFGGGTKVEI	KRTVAAPSVF	IFPPSDEQLK	SGTASVVCCL	NNFYPREAKV	150'
QWKVDNALQS	GNSQESVTEQ	DSKSTYSLSL	STLTLSKADY	EKHKQYACEV	200'
THQGLSSPVT	KSFNRGEC				218'

## Disulfide bridges

22-96	22"-96"	23'-92'	23'''-92'''	134-218'	134"-218"	138'-198'	138'''-198'''
147-203	147"-203"	226-226"	229-229"	261-321	261"-321"	367-425	367"-425"

## Glycosylation sites (N)

Asn-297 Asn-297"

MOLECULAR FORMULA C<sub>6504</sub>H<sub>10004</sub>N<sub>1716</sub>O<sub>2036</sub>S<sub>46</sub> (peptide)

MOLECULAR WEIGHT 146.3 kDa (peptide)

TRADEMARK None as yet

PEMBROLIZUMAB

N13

Page 2 of 2

140

SPONSOR

Merck Sharp & Dohme Corp.

CAS REGISTRY NUMBER

1374853-91-4

WHO NUMBER

9798

\*This adoption statement supercedes and replaces N13/06 (lambrolizumab), which is hereby rescinded.

gbk